Please assess the completion status of the following clinical trial:

Trial Title: A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects with good general health as judged by the Investigator~* Body weight of 65.0-95.0 kg (both inclusive)~* Body Mass Index (BMI) of 18.5-27.5 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Known or suspected allergy to trial product or related products~* Acute infection or inflammation or other illness that may confound the results of the trial or pose a risk to the subject by administering the trial product, as judged by the Investigator~* Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) or malabsorptive states (celiac disease, lactose intolerance or chronic pancreatitits), as judged by the Investigator

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Trial part 1 (Type: EXPERIMENTAL): None
- Trial part 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).